The study was conducted by the Southwest Oncology Group (SWOG), a cancer center network sponsored by the National Cancer Institute. SWOG will engage with ImClone and Bristol-Myers Squibb in order to examine the data in more detail.
“We still consider pancreatic cancer to be of the utmost priority and we intend to pursue additional evaluations with Erbitux including a pilot study of Erbitux and bevacizumab with or without gemcitabine, as well as our pipeline agents, to improve the outcome for patients with pancreatic cancer.” stated Eric Rowinsky, senior vice president of ImClone Systems.
Erbitux is already approved to treat colorectal cancer and head and neck cancer and is the only approved product in ImClone's pipeline.